Anti-CD19 Antibody and NK Cell Combination for Synergistic Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for CD19-expressing tumors, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia, lack effective methods with synergistic therapeutic effects.
Innovation Solution
A pharmaceutical combination of an anti-CD19 antibody and natural killer cells, specifically engineered to enhance ADCC activity, is administered separately or simultaneously to target and kill B-cell malignant tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for CD19-expressing tumors are used, then treatment is simpler, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines anti-CD19 antibody and natural killer cells into a single pharmaceutical composition, allowing simultaneous delivery of both therapeutic agents. This merging approach enhances therapeutic efficacy through synergistic effects while simplifying the treatment administration process, as both components are delivered together rather than requiring separate administration protocols
2Reliability
If natural killer cells are used alone, then cell-based therapy is provided, but killing efficacy against B-cell malignant tumors is insufficient
Solution Approach 1:
The anti-CD19 antibody serves as an intermediary that bridges the natural killer cells and the B-cell malignant tumors. The antibody binds to CD19 antigens on tumor cells and facilitates NK cell recognition and killing through antibody-dependent cellular cytotoxicity (ADCC), thereby enhancing the killing efficacy of NK cells against CD19-expressing tumors without requiring complex engineering of the NK cells themselves
3Reliability
If anti-CD19 antibody is used alone, then antibody therapy is provided, but synergistic therapeutic effect is not achieved
Solution Approach 1:
The patent merges anti-CD19 antibody and natural killer cells into a single pharmaceutical composition, enabling synergistic therapeutic effects through combined mechanisms of action. The antibody provides targeted binding to CD19 while NK cells deliver cytotoxic effects, and their combination in one formulation allows for enhanced tumor cell killing that exceeds the sum of individual components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination exhibits synergistic effects in vitro and in vivo, significantly enhancing the killing efficacy of B-cell malignant tumors with high cell survival rates and long-term storability.
Implementation Method 1
anti-CD19 antibodies can bind to CD19 antigens as targets
Implementation Method 2
specifically engineered to enhance ADCC activity
Implementation Method 3
the natural killer cells play a role of directly killing a malignant tumor
Data Source
AI summary
Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.